Scotia Capital’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Scotia Capital’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,000	Closed	-$7K	–	740
2020 Q1	$7K	Hold	19,000	–	–	﹤0.01%	630
2019 Q4	$8K	Hold	19,000	–	–	﹤0.01%	732
2019 Q3	$36K	Hold	19,000	–	–	﹤0.01%	705
2019 Q2	$40K	Hold	19,000	–	–	﹤0.01%	709
2019 Q1	$58K	Hold	19,000	–	–	﹤0.01%	678
2018 Q4	$44K	Sell	19,000 -120	-0.6%	-$399	﹤0.01%	637
2018 Q3	$76K	Buy	+19,120	New	+$84.3K	﹤0.01%	696
2018 Q2	–	Sell	-19,120	Closed	-$44K	–	697
2018 Q1	$44K	Hold	19,120	–	–	﹤0.01%	686
2017 Q4	$29K	Hold	19,120	–	–	﹤0.01%	702
2017 Q3	$40K	Buy	+19,120	New	+$65K	﹤0.01%	686

Scotia Capital's CORV Position: Q2 2020 in Review

Scotia Capital sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q2 2020, closing a stake of 19,000 shares — an estimated $7K sold.

Scotia Capital first reported a position in CORV in Q3 2017 and held it in 10 quarters. The position peaked at $76K in Q3 2018. 0 funds tracked by Wall St. Rank hold CORV as of Q2 2020.

Scotia Capital reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q2 2020 after selling out during the quarter.
Scotia Capital sold 19,000 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q2 2020, an estimated $7K.
Scotia Capital first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q3 2017 and held it in 10 quarters.
Scotia Capital's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $76K in Q3 2018.
0 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q2 2020.

Based on Scotia Capital's 13F filing for Q2 2020, filed 11 Aug 2020.